Buy Johnson & Johnson (JNJ) Stock for Higher Highs?

Zacks

03-05

Markets have continued to sell off this week as investors digest ensuing tariff implications and rising geopolitical tensions. That said, one stock that continues to stand out is Johnson & Johnson JNJ.

The pharmaceutical giant's stock hit new 52-week highs of nearly $170 on Tuesday, with JNJ now up +16% year to date. Seemingly acting as a defensive hedge against recent market volatility, let's see if it's time to buy JNJ shares for higher highs.

Image Source: Zacks Investment Research

J&J’s Diversification

Of course, medical stocks are often sought during broader economic uncertainty as the essentiality of healthcare doesn’t waver.

What strengthens Johnson & Johnson’s defensive capabilities is the company’s diversification within the medical sector. Johnson & Johnson provides a wide range of pharmaceuticals across several therapeutic areas including oncology, immunology, and neuroscience among others.

In addition to this, Johnson & Johnson’s medical device division offers solutions and operational equipment for orthopedics, advanced surgical procedures, and vision care. Bringing in $88.82 billion in 2024, Johnson & Johnson's top line is expected to rise 1% this year and is projected to increase another 3% in fiscal 2026 to $92.8 billion.

Image Source: Zacks Investment Research

EPS Growth

More intriguing, Johnson & Johnson’s annual earnings are slated to rise 6% this year to $10.58 per share, compared to EPS of $9.98 in 2024. Plus, FY26 EPS is projected to increase another 4%.

Image Source: Zacks Investment Research

Monitoring J&J’s Valuation

At current levels, JNJ still trades at a very reasonable 15.8X forward earnings multiple. This is a noticeable discount to the benchmark S&P 500’s 22X and its Zacks Large Cap Pharmaceuticals Industry average of 18.1X, with some other notable names in the space being AbbVie ABBV, Eli Lilly LLY and Pfizer PFE.

Image Source: Zacks Investment Research

JNJ also trades beneath its decade-long median of 16.4X forward earnings with a high of 20.1X over the last 10 years. Less prone to major fluctuations in its valuation, it’s noteworthy that JNJ has a beta ratio under 1.0 (0.47) which suggests this stock should be less volatile than the benchmark when considering market risk.

Image Source: Zacks Investment Research

Bottom Line

After such a sharp YTD rally, Johnson & Johnson stock lands a Zacks Rank #3 (Hold). Near 52-week peaks there could be better buying opportunities for JNJ shares but higher highs wouldn’t be surprising.

To that point, investors may be compelled to hold JNJ as a hedge against recent market volatility, especially considering Johnson & Johnson’s steady growth and reasonable valuation.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Johnson & Johnson (JNJ) : Free Stock Analysis Report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2517693367"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517693367\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2517693367?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 06:26","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2517693367","market":"us","top_or_hot":-1,"title":"Buy Johnson & Johnson (JNJ) Stock for Higher Highs?","media":"Zacks","content":"<html><body><p><span><span>Markets have continued to sell off this week as investors digest ensuing tariff implications and rising geopolitical </span></span><span>tensions. That said, one stock that continues to stand out is Johnson & Johnson </span>JNJ<span>.</span></p>\n<p><span><span>The pharmaceutical giant's stock hit new 52-week highs of nearly $170 on Tuesday, with JNJ now up +16% year to date. Seemingly acting as a defensive hedge against recent market volatility, let's see if it's time to buy JNJ shares for higher highs.  </span></span></p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/Pndqe6RCf4OinuhGmujsLg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/7e1560dc60522b18187c2732cd0fb8ea\"/><br/><span>Image Source: Zacks Investment Research</span><br/></p>\n<h2><span><span><strong>J&J’s Diversification</strong></span></span></h2>\n<p><span><span>Of course, medical stocks are often sought during broader economic uncertainty as the essentiality of healthcare doesn’t waver.</span></span></p>\n<p><span><span>What strengthens Johnson & Johnson’s defensive capabilities is the company’s diversification within the medical sector. Johnson & Johnson provides a wide range of pharmaceuticals across several therapeutic areas including oncology, immunology, and neuroscience among others. </span></span></p>\n<p><span><span>In addition to this, Johnson & Johnson’s medical device division offers solutions and operational equipment for orthopedics, advanced surgical procedures, and vision care. Bringing in $88.82 billion in 2024, Johnson & Johnson's top line is expected to rise 1% this year and is projected to increase another 3% in fiscal 2026 to $92.8 billion.</span></span></p>\n<p><img src=\"https://s.yimg.com/uu/api/res/1.2/Eo9oM9009.QeUfA2BZDknQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/2fa17e6fadeeb2c717111ca6794f799e\"/><br/><span>Image Source: Zacks Investment Research</span><br/></p>\n<h2><span><span><strong>EPS Growth </strong></span></span></h2>\n<p><span><span>More intriguing, Johnson & Johnson’s annual earnings are slated to rise 6% this year to $10.58 per share, compared to EPS of $9.98 in 2024. Plus, FY26 EPS is projected to increase another 4%.</span></span></p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/t7QCNJvr_36rrQ9IBcYkgQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/cd38902bd8eaeecd3668e94901c2d717\"/><br/><span>Image Source: Zacks Investment Research</span><br/></p>\n<h2><span><span><strong>Monitoring J&J’s Valuation </strong></span></span></h2>\n<p><span><span>At current levels, JNJ still trades at a very reasonable 15.8X forward earnings multiple. This is a noticeable discount to the benchmark S&P 500’s 22X and its Zacks Large Cap Pharmaceuticals Industry average of 18.1X, with some other notable names in the space being AbbVie ABBV</span></span><span><span>, Eli Lilly LLY</span></span><span><span> and Pfizer PFE</span></span><span><span>.</span></span></p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/L7hGawr3WKVUHOAIC0mLCg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/fb86ebf3ad08783c2da3fe27bf60a3c4\"/><br/><span>Image Source: Zacks Investment Research</span><br/></p>\n<p><span>JNJ also trades beneath its decade-long median of 16.4X forward earnings with a high of 20.1X over the last 10 years. Less prone to major fluctuations in its valuation, it’s noteworthy that JNJ has a beta ratio under 1.0 (0.47) which suggests this stock should be less volatile than the benchmark when considering market risk.</span></p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/RZ5FpsOipdzh0dIXU3E8pg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/4123c4496b4e4897b7e52f394bba89ad\"/><br/><span>Image Source: Zacks Investment Research</span><br/></p>\n<p><strong>Bottom Line</strong></p>\n<p><span><span>After such a sharp YTD rally, Johnson & Johnson stock lands a Zacks Rank #3 (Hold). Near 52-week peaks there could be better buying opportunities for JNJ shares but higher highs wouldn’t be surprising.  </span></span></p>\n<p><span><span>To that point, investors may be compelled to hold JNJ as a hedge against recent market volatility, especially considering Johnson & Johnson’s steady growth and reasonable valuation.   </span></span></p>\n<p>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report</p>\n<p>Johnson & Johnson (JNJ) : Free Stock Analysis Report</p>\n<p>Pfizer Inc. (PFE) : Free Stock Analysis Report</p>\n<p>Eli Lilly and Company (LLY) : Free Stock Analysis Report</p>\n<p>AbbVie Inc. (ABBV) : Free Stock Analysis Report</p>\n<p>This article originally published on Zacks Investment Research (zacks.com).</p>\n<p>Zacks Investment Research</p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Buy Johnson & Johnson (JNJ) Stock for Higher Highs?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuy Johnson & Johnson (JNJ) Stock for Higher Highs?\n</h2>\n<h4 class=\"meta\">\n</h4><p class=\"head\">\n<strong class=\"h-name small\">Zacks</strong><span class=\"h-time small\">2025-03-05 06:26</span>\n</p>\n</header>\n<article>\n<p><span><span>Markets have continued to sell off this week as investors digest ensuing tariff implications and rising geopolitical </span></span><span>tensions. That said, one stock that continues to stand out is Johnson & Johnson </span>JNJ<span>.</span></p>\n<p><span><span>The pharmaceutical giant's stock hit new 52-week highs of nearly $170 on Tuesday, with JNJ now up +16% year to date. Seemingly acting as a defensive hedge against recent market volatility, let's see if it's time to buy JNJ shares for higher highs.  </span></span></p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/Pndqe6RCf4OinuhGmujsLg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/7e1560dc60522b18187c2732cd0fb8ea\"/><br/><span>Image Source: Zacks Investment Research</span><br/></p>\n<h2><span><span><strong>J&J’s Diversification</strong></span></span></h2>\n<p><span><span>Of course, medical stocks are often sought during broader economic uncertainty as the essentiality of healthcare doesn’t waver.</span></span></p>\n<p><span><span>What strengthens Johnson & Johnson’s defensive capabilities is the company’s diversification within the medical sector. Johnson & Johnson provides a wide range of pharmaceuticals across several therapeutic areas including oncology, immunology, and neuroscience among others. </span></span></p>\n<p><span><span>In addition to this, Johnson & Johnson’s medical device division offers solutions and operational equipment for orthopedics, advanced surgical procedures, and vision care. Bringing in $88.82 billion in 2024, Johnson & Johnson's top line is expected to rise 1% this year and is projected to increase another 3% in fiscal 2026 to $92.8 billion.</span></span></p>\n<p><img src=\"https://s.yimg.com/uu/api/res/1.2/Eo9oM9009.QeUfA2BZDknQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/2fa17e6fadeeb2c717111ca6794f799e\"/><br/><span>Image Source: Zacks Investment Research</span><br/></p>\n<h2><span><span><strong>EPS Growth </strong></span></span></h2>\n<p><span><span>More intriguing, Johnson & Johnson’s annual earnings are slated to rise 6% this year to $10.58 per share, compared to EPS of $9.98 in 2024. Plus, FY26 EPS is projected to increase another 4%.</span></span></p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/t7QCNJvr_36rrQ9IBcYkgQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/cd38902bd8eaeecd3668e94901c2d717\"/><br/><span>Image Source: Zacks Investment Research</span><br/></p>\n<h2><span><span><strong>Monitoring J&J’s Valuation </strong></span></span></h2>\n<p><span><span>At current levels, JNJ still trades at a very reasonable 15.8X forward earnings multiple. This is a noticeable discount to the benchmark S&P 500’s 22X and its Zacks Large Cap Pharmaceuticals Industry average of 18.1X, with some other notable names in the space being AbbVie ABBV</span></span><span><span>, Eli Lilly LLY</span></span><span><span> and Pfizer PFE</span></span><span><span>.</span></span></p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/L7hGawr3WKVUHOAIC0mLCg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/fb86ebf3ad08783c2da3fe27bf60a3c4\"/><br/><span>Image Source: Zacks Investment Research</span><br/></p>\n<p><span>JNJ also trades beneath its decade-long median of 16.4X forward earnings with a high of 20.1X over the last 10 years. Less prone to major fluctuations in its valuation, it’s noteworthy that JNJ has a beta ratio under 1.0 (0.47) which suggests this stock should be less volatile than the benchmark when considering market risk.</span></p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/RZ5FpsOipdzh0dIXU3E8pg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/4123c4496b4e4897b7e52f394bba89ad\"/><br/><span>Image Source: Zacks Investment Research</span><br/></p>\n<p><strong>Bottom Line</strong></p>\n<p><span><span>After such a sharp YTD rally, Johnson & Johnson stock lands a Zacks Rank #3 (Hold). Near 52-week peaks there could be better buying opportunities for JNJ shares but higher highs wouldn’t be surprising.  </span></span></p>\n<p><span><span>To that point, investors may be compelled to hold JNJ as a hedge against recent market volatility, especially considering Johnson & Johnson’s steady growth and reasonable valuation.   </span></span></p>\n<p>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report</p>\n<p>Johnson & Johnson (JNJ) : Free Stock Analysis Report</p>\n<p>Pfizer Inc. (PFE) : Free Stock Analysis Report</p>\n<p>Eli Lilly and Company (LLY) : Free Stock Analysis Report</p>\n<p>AbbVie Inc. (ABBV) : Free Stock Analysis Report</p>\n<p>This article originally published on Zacks Investment Research (zacks.com).</p>\n<p>Zacks Investment Research</p>\n<div class=\"bt-text\">\n<p> 來源：<a href=\"https://finance.yahoo.com/news/buy-johnson-johnson-jnj-stock-222600569.html\">Zacks</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2602419157.SGD","symbol_name":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/buy-johnson-johnson-jnj-stock-222600569.html","article_id":"2517693367","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517693367","pubTimestamp":1741127160,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The pharmaceutical giant's stock hit new 52-week highs of nearly $170 on Tuesday, with JNJ now up +16% year to date. Seemingly acting as a defensive hedge against recent market volatility, let's see if it's time to buy JNJ shares for higher highs.Of course, medical stocks are often sought during broader economic uncertainty as the essentiality of healthcare doesn’t waver.What strengthens Johnson & Johnson’s defensive capabilities is the company’s diversification within the medical sector. Johnson & Johnson provides a wide range of pharmaceuticals across several therapeutic areas including oncology, immunology, and neuroscience among others.In addition to this, Johnson & Johnson’s medical device division offers solutions and operational equipment for orthopedics, advanced surgical procedures, and vision care. Bringing in $88.82 billion in 2024, Johnson & Johnson's top line is expected to rise 1% this year and is projected to increase another 3% in fiscal 2026 to $92.8 billion.Eli Lilly ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","JNJ":"强生","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","ABBV":"艾伯维公司","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","BK4504":"桥水持仓","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","BK4516":"特朗普概念","BK4592":"伊斯兰概念","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD"},"translate_title":"购买强生公司(JNJ)股票以获得更高的高点？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1,"JNJ":1},"content_text":"Markets have continued to sell off this week as investors digest ensuing tariff implications and rising geopolitical tensions. That said, one stock that continues to stand out is Johnson & Johnson JNJ.\nThe pharmaceutical giant's stock hit new 52-week highs of nearly $170 on Tuesday, with JNJ now up +16% year to date. Seemingly acting as a defensive hedge against recent market volatility, let's see if it's time to buy JNJ shares for higher highs.  \nImage Source: Zacks Investment Research\nJ&J’s Diversification\nOf course, medical stocks are often sought during broader economic uncertainty as the essentiality of healthcare doesn’t waver.\nWhat strengthens Johnson & Johnson’s defensive capabilities is the company’s diversification within the medical sector. Johnson & Johnson provides a wide range of pharmaceuticals across several therapeutic areas including oncology, immunology, and neuroscience among others. \nIn addition to this, Johnson & Johnson’s medical device division offers solutions and operational equipment for orthopedics, advanced surgical procedures, and vision care. Bringing in $88.82 billion in 2024, Johnson & Johnson's top line is expected to rise 1% this year and is projected to increase another 3% in fiscal 2026 to $92.8 billion.\nImage Source: Zacks Investment Research\nEPS Growth \nMore intriguing, Johnson & Johnson’s annual earnings are slated to rise 6% this year to $10.58 per share, compared to EPS of $9.98 in 2024. Plus, FY26 EPS is projected to increase another 4%.\nImage Source: Zacks Investment Research\nMonitoring J&J’s Valuation \nAt current levels, JNJ still trades at a very reasonable 15.8X forward earnings multiple. This is a noticeable discount to the benchmark S&P 500’s 22X and its Zacks Large Cap Pharmaceuticals Industry average of 18.1X, with some other notable names in the space being AbbVie ABBV, Eli Lilly LLY and Pfizer PFE.\nImage Source: Zacks Investment Research\nJNJ also trades beneath its decade-long median of 16.4X forward earnings with a high of 20.1X over the last 10 years. Less prone to major fluctuations in its valuation, it’s noteworthy that JNJ has a beta ratio under 1.0 (0.47) which suggests this stock should be less volatile than the benchmark when considering market risk.\nImage Source: Zacks Investment Research\nBottom Line\nAfter such a sharp YTD rally, Johnson & Johnson stock lands a Zacks Rank #3 (Hold). Near 52-week peaks there could be better buying opportunities for JNJ shares but higher highs wouldn’t be surprising.  \nTo that point, investors may be compelled to hold JNJ as a hedge against recent market volatility, especially considering Johnson & Johnson’s steady growth and reasonable valuation.   \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nJohnson & Johnson (JNJ) : Free Stock Analysis Report\nPfizer Inc. (PFE) : Free Stock Analysis Report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nAbbVie Inc. (ABBV) : Free Stock Analysis Report\nThis article originally published on Zacks Investment Research (zacks.com).\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}